<DOC>
	<DOCNO>NCT01476423</DOCNO>
	<brief_summary>This observational registry conduct Europe , Asia , Africa United States America ( USA ) . The purpose registry evaluate efficacy safety activate recombinant human factor VII ( rFVIIa ) bleed episodes prevention bleed invasive procedures/surgery patient Glanzmann 's thrombasthenia ( GT ) past present refractoriness platelet transfusion . Attention direct towards complication related thrombo-embolic event concomitant medication especially antifibrinolytics .</brief_summary>
	<brief_title>Observational Registry Treatment Glanzmann 's Thrombasthenia</brief_title>
	<detailed_description />
	<mesh_term>Blood Coagulation Disorders</mesh_term>
	<mesh_term>Hemostatic Disorders</mesh_term>
	<mesh_term>Thrombasthenia</mesh_term>
	<criteria>Patients congenital GT define patient lifelong bleeding tendency characterise impaired absent platelet aggregation , impaired clot retraction prolong bleeding time prolonged platelet function analyser closure time . The patient normal platelet count platelet morphology . Optional diagnosis criterion quantitative qualitative evaluation GP ( Glycoprotein ) IIb/IIIa receptor include flow cytometry identification gene defect Signed informed consent patient next kin legally acceptable representative collect data treatment give bleed episode surgical event specify protocol . If informed consent provide next kin legally acceptable representative , consent must also obtain patient soon he/she able . Informed consent must obtain entry data registry Patients acquire thrombasthenic state cause autoimmune disorder ( acute chronic ) drug</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Glanzmann 's Thrombasthenia</keyword>
</DOC>